Thyroid and Anti-thyroid Flashcards
synthesis and secretion of thyroid hormones - steps
- cellular uptake of iodide by follicular cells (sodium-iodide symporters)
- oxidation of iodide to iodine, rapid iodination of tyrosine residues on thyroglobulin molecules to form mono-iodo-tyrosine and di-iodo-tyrosine by the enzyme thyroid peroxidase that is present as an integral membrane protein on the apical membrane of each thyrocyte (organification)
- coupling of iodine residues on thyroglobulin molecules (also carried out by thyroid peroxidase), storage as colloid in the follicular lumen
> couple can yield T3 (mono+di) or T4 (di+di) - resorption of colloid found in the follicular lumen into the thyrocyte at the apical lumen by endocytosis, then into lysosomes
- proteolysis of thyroglobulin by lysozymes,
- release into bloodstream
<><>
binding of thyrotropin (TSH) from the anterior pituitary to its receptor on the thyrocyte stimulates the steps in synthesis and release of the hormones by each thyrocyte in the gland
T4:T3 is released in what ratio
§T4:T3 is released in a ~4:1 ratio by thyroid
what proportion of thyroid is bound to Thyroid Binding Globulin
§ Circulate bound to Thyroid Binding Globulin; ~99%
elimination half-life of T4 and T3 in dog
§ Elimination half-life: T4 (12-16 hrs) vs T3 (5-6 hrs)
- Peripheral conversion of T4 to T3 by what enzyme?
- why bother with this?
- is T4 or T3 more potent?
- T4 acts as what?
§ Peripheral conversion of T4 to T3 by 5’-deiodinase (mainly in liver)
§ Maintains intracellular control over T3 production
§ T3 has 3-10x the biologic potency as T4
§ T4 acting as a prohormone
hypothyroidism
- dogs cats horses: in which is it common vs rare
§ Common in dogs, rare in cats, horses
primary vs secondary hypothyroidism
- which is more common?
- causes?
Primary (thyroid-based)-most common form
§ Acquired (nearly all)
> lymphocytic thyroiditis; ~50% of primary cases
> idiopathic follicular atrophy
> neoplastic destruction
§ Congenital
> disorders of dyshormonogenesis, iodine deficiency
<><><><>
Secondary (pituitary-based)-rare
§ Acquired
> pituitary masses
§ Congenital
> dwarfism, dyshormonogenesis, receptor defects
most common cause of primary hypothyroidism
lymphocytic thyroiditis, ~50% of primary cases
clinical signs of hypothyroidism
Manifest as a slowing of bodily functions:
§ CNS, cardiovascular and energy metabolism
<><><><>
§ Weight gain (obesity)
§ Lethargy, weakness, unwillingness to exercise
§ Cold intolerance/heat seeking
§ Dermatology
> poor coat quality, alopecia, seborrhea,
> hyperpigmentation
> 2° pyoderma and pruritus
§ Bradycardia
§ Abnormal estrous, infertility, lack of libido
hypothyroidism therapy
- drug of choice? why?
§ L-thyroxine (T4) is drug of choice for replacement therapy in clinical hypothyroidism regardless of cause
§ T4 almost always indicated for the life of the dog once diagnosed with hypothyroidism
<><><><>
Advantages:
§ Longer half-life allows for once daily dosing
§ T4 is main circulating thyroid hormone versus T3
§ Easily monitored in plasma
§ T4 does not bypass cellular regulatory process
controlling the production of T3 from T4
advantages of giving T4 instead of T3 for hypothyroid therapy
§ Longer half-life allows for once daily dosing
§ T4 is main circulating thyroid hormone versus T3
§ Easily monitored in plasma
§ T4 does not bypass cellular regulatory process
controlling the production of T3 from T4
synthetic preparations of T4 available
Several synthetic preparations available
§ Thyro-Tabs®, Leventa®- licensed in dogs
§ 0.1-0.8 mg tablets, oral solution (1 mg/mL)
§ a daily total dosage of 20 μg/kg is indicated that can
be given once daily, or divided and given twice daily
dosing regimen for T4 therapy
- consideration for once or twice daily dosing
Dividing the daily dosage can be beneficial regarding T4 pharmacokinetics in early treatment, with once daily dosing following stabilization of the patient; owner compliance can be a concern with twice daily dosing
how to monitor T4 therapy
- when to start?
- what should T4 levels be at different T4 doses
- monitoring for first months vs later
- brand change?
§ Monitoring requires time for resolution of clinical signs
> Usually monitor ~4 weeks after therapy begun
> Ideally; T4 in reference range prior to dosing and high normal 4-6 hours after once daily dosing; twice daily dosing can be checked anytime
<><>
§ Monitoring every ~8 weeks recommended for the first 6-8 months
> T4 metabolism changes as metabolic rate normalizes
> Subsequently monitor 1-2X a year
<><>
§ If brand is changed; monitor serum levels at 4-8 weeks after switching
T4 therapy for hypothyroidism
- when will we see clinical improvement?
- what will we see?
§ Clinical improvement should be evident in 1-2 weeks
> Increased activity level
§ Weight loss evident in ~8 weeks
§ Normal hair coat may take months